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Linear IgA bullous dermatosis (LAD) is an autoimmune, 
chronic bullous disease affecting primarily young child-
ren and adults. Studies on LAD are relatively sparse and 
from Scandinavia we could only find a few case reports. 
Therefore we decided to conduct a retrospective investi-
gation of patients seen at our department since 1972.  A 
total of 23 patients were identified; 7 children (F:M ratio 
0.75) and 16 adults (F:M ratio 0.78).  Mean age at disease 
onset in the two age groups were 2.7 and 56.8 years. Es-
timated incidence rate in our region:  0.67 per million 
per year. The most commonly used treatment modalities 
were corticosteroids, dapsone and sulphapyridine. Key 
words: IgA; bullous disease; autoimmune disease; chro-
nic bullous disease of childhood; treatment; incidence; 
Naranjo algorithm.
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Linear IgA bullous dermatosis (LAD) is a rare, autoim-
mune, chronic bullous disease affecting young children 
and adults. Childhood onset LAD is also named chronic 
bullous disease of childhood (CBDC) and is characte-
rised by the development of papulovesicles and larger 
bulla primarily around the mouth and eyes, lower abdo-
men, thighs, buttocks, genitals, wrists and ankles (Fig. 1 
and Fig. 2). The lesions can be annular or polycyclic 
urticarial plaques with a characteristic blistering along 
the edge of the lesion, the so-called “string-of-pearls” 
sign (Fig. 1B). Involvement of the mucosa can be seen. 
The subjective symptoms are variable from almost none 
or mild pruritus to severe burning.
The adult-onset form of LAD has a slightly different 
presentation with lesions on the trunk (Fig. 1D) and 
sometimes head and limbs. The blisters arise on urti-
carial looking plaques or normal skin. Mucosa can be 
affected. The string-of-pearls sign is less common in 
adults compared with the childhood form (1).
Histological characteristic features include a sub-
epithelial blister formation with neutrophils along the 
basement membrane zone (BMZ). Direct immunofluo-
rescence typically shows a linear IgA deposition along 
the BMZ, in some cases both IgA and IgG while rarely 
IgM and C3 can be seen (2).
Studies on LAD are relatively sparse and most of 
the publications are small series or single case reports. 
From Scandinavia we could only find a few case reports 
(3–6). Therefore, we decided to conduct a retrospective 
investigation of patients seen at our department since 
1972. The objective is to give a description of the dif-
ferent subgroups of patients with LAD with regard to 
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Fig. 1. Linear IgA bullous dermatosis. (A) Numerous tense bullae on neck and face including periorbital and perioral area (patient No. 5). (B) “String-
of-pearls” sign (patient No. 5). (C) Polycyclic bullae on urticarial looking plaques characteristically localised in the genital region (patient No. 6). (D) 
Maculopapular lesions symmetrically distributed on the back (patient No. 9).
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precipitating factors, demographics, treatments, course 
of disease, and differential diagnoses. 
Furthermore, our study is the first study to give an 
estimated incidence rate of the disease in our region.
METHODS
After approval from the records of patients with LAD seen at 
the Department of Dermatology, Odense University Hospital, 
Denmark from the beginning of January 1972 until January 
2014 were reviewed. Inclusion criteria from 1972–1994 were 
the ICD8-diagnosis 693.09 Linear IgA dermatosis. From 
January 1994 until January 2014 inclusion criteria were the 
ICD-10 diagnoses L 13.8 Other specified bullous disorders, and 
L12.2 Chronic bullous disease of childhood.
Patient data regarding age at disease onset, gender, medical 
associations, medications, immunofluorescence findings, other 
investigations, disease duration, treatment, and tentative diag-
nosis were recorded.
RESULTS
A total of 23 patients were identified; 7 children and 
16 adults.
Children
The child group (Table I) included 4 boys 
and 3 girls (F:M ratio 0.75). Their mean age 
at disease onset in childhood was 2.7 years 
(range 11 months–4 years, median 3 years). 
The most common initial tentative clinical 
diagnoses were bullous impetigo (n = 3), 
erythema multiforme (n = 2), herpes simplex 
(n = 1) and chickenpox (n = 1).
Direct immunofluorescence was perfor-
med in all cases and showed linear IgA de-
position. One had a combined linear IgA/IgG 
deposition. Indirect immunofluorescence 
investigation was performed in 3 cases and 2 
of these were positive. None of the children 
had a history of drug intake.
Four of the children were primarily treated 
with dapsone, and 3 of these later switched 
to treatment with sulphapyridine. Three of 
the children were primarily treated with 
sulphapyridine but later changed to treatment with 
dapsone. Three patients received concomitant systemic 
prednisone with a dosage of 0.5–1 mg/kg/day. Typical 
dapsone dosage was 0.5–2 mg/kg/day and sulphapyri-
dine dosage was 100–200 mg/kg/day. 
The reasons for changing treatment modalities were 
poor response or side effects (fever, rash, malaise). The 
mean duration of treatment was 3.2 years (range 2–6 
years, median 3 years).
Adults
Among 16 adults with LAD (Table II) there were 7 
women and 9 men (F:M ratio: 0.78). The mean age 
at time of disease onset was 56.8 years (range 23–79 
years, median 63.5 years). 
The tentative clinical diagnoses in the adult group 
were bullous pemphigoid (n = 4), dermatitis herpetifor-
mis (n = 2), Stevens-Johnsons syndrome (n = 2), eczema 
(n = 2), bullous dermatitis not specified (n = 2), erythema 
multiforme (n = 1), bullous impetigo (n = 1) acquired 
epidermolysis bullosa (n = 1) and dermato phytosis (n = 1).
Fig. 2. Linear IgA bullous dermatosis. Patient nr. 5 before (A) and after (B) 7 months 
treatment.
Table I. Seven children with linear IgA dermatosis, all with complete response
Pat. 
No.
Age, 
years/sex Direct IF Indirect IF HLA-B8 Treatment
Duration of 
treatment
Tentative diagnosis  
at presentation
1 3/M Linear IgA + + Sulphapyridine, Dapsone, Prednisolone 6 years Bullous impetigo
2 2/M Linear IgA – + Dapsone, Prednisolone, Sulphapyridine 2 years Bullous erythema multiforme
3 0.9/F Linear IgA ND ND Dapsone, Sulphapyridine 3 years Herpes or erythema multiforme
4 3/M Linear IgA ND + Topical steroid, Dapsone 3 years Varicella
5 4/F Linear IgA + + Dapsone, Prednisolone, Sulphapyridine 1.5 years Bacterial infection
6 2/M Combined 
linear IgA/IgG
ND ND Sulphapyridine, Prednisolone, Dapsone 3 years Bullous impetigo
7 3/F Linear IgA ND ND Sulphapyridine, Dapsone 4 years Bullous impetigo
IF: immunofluorescence; ND: Not done; +: positive; –: negative.
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Direct immunofluorescence in all cases showed linear 
deposition of IgA at the BMZ. One patient had mixed 
IgA/IgG deposition, 2 patients an IgA/C3 deposition 
and 2 had a linear IgA/IgG/C3 deposition – one of these 
(No. 23) had granular deposition as well.
Indirect immunofluorescence was performed in 2 
cases and in both of them was negative.
Six out of 16 adult cases were presumed to be drug 
induced (various antibiotics, fluconazole, NSAIDs, ve-
rapamil, digoxin, loperamide and metoclopramide). In 
5 of 6 cases, 2 or more drugs were potentially involved. 
All patients went into remission after withdrawal of the 
culprit drugs and temporary treatment with topical or 
systemic corticosteroid. Mean duration of disease was 
6 months (range 1–24 months, median 2.5 months). 
Mean age at disease onset in the drug-induced group 
was 66.5 years (range 49–79 years, median 66.5 years).
All patients with drug-induced LAD suffered from 
other diseases. One of the patients had bladder cancer as 
well as arteritis temporalis. Other concomitant diseases 
were diabetes, heart- and lung diseases, alcoholism, and 
multiple sclerosis.
One of the patients with idiopathic LAD (non drug-
induced LAD) was diagnosed with coeliac disease, 
myelodysplastic syndrome and paroxysmal nocturnal 
haemoglobinuria.
Interestingly, 40% of the patients with idiopathic 
LAD, but none in the drug-induced group, showed a 
deposition of C3. Mean age at onset in the idiopathic 
group was 51 years (range 23–73 years, median 50.5 
years), the F:M ratio was 1.0.
All the patients in the idiopathic adult group respon-
ded well to therapy with dapsone alone or in combina-
tion with prednisone. Two patients were initially treated 
with prednisone/azathioprine and prednisone/sulpha-
pyridine, respectively, but were later on changed to 
monotherapy with dapsone. Mean duration of treatment 
in the idiopathic group was 6.9 years (range 1–22 years, 
median 3 years). Mean duration of treatment in the adult 
LAD group overall was 4.1 years (range 1 month–22 
years, median 2 years). In most cases the duration of 
disease was relatively short but in 2 cases the patients 
needed continuous treatment to prevent relapse. Two 
recent cases were not included in these calculations 
since they just recently started treatment (cases 22 and 
23). The typical doses used for the treatment of adult 
LAD were 0.5–1 mg prednisone kg/day and/or 50–150 
mg dapsone/day. Four children and 2 adults were found 
to be HLA-B8 positive.
Incidence
In the 20-year period from 1994–2013 we found 16 
incident cases of LAD (infant and adult form). The 
background population of our department is 1.2 mil-
lion persons, which gives an incidence rate of 0.67/
million/year.
DISCUSSION
We present the first larger case-series of Scandinavian 
patients with LAD, data which illustrates the hetero-
geneity of this disease.
An increasing incidence of LAD in our region is 
likely, as 7 patients were diagnosed in the first 22 years 
and 16 patients were diagnosed within the last 20 years. 
This finding may partly be due to a lack of diagnostic 
consensus in the 1970s and 1980s and partly due to a 
change in the referral pattern to our department. In 1994 
the Danish disease-registration system was changed from 
ICD-8 to ICD-10 and the data retrieved prior to 1994 
may be incomplete. Hence, the incidence rate calcula-
tion is based on data from 1994 until beginning of 2014. 
Patients may also be treated by local dermatologists and 
hence our incidence rate might be underestimated. The 
rate, though, is comparable to and even slightly higher 
than the incidence rates found in a German study: 0.23/
million/year (7) and a French study: 0.49/million/year 
(8). In Kuwait, an age-adjusted incidence rate for CBDC 
of 2.3/million/year was found (9). 
We have subdivided the adult LAD group into 2 
groups with different characteristics: a drug-induced 
group and an idiopathic group.
The drug-induced cases represent 37.5% of the adult 
LAD cases in our series. These patients are generally 
older than idiopathic cases (mean age 66.5 years ver-
sus 51 years) and more likely they are of male gender 
(F:M ratio 0.5 versus 1.0). However, it must be kept 
in mind that the probability of receiving medications 
increase with age as does the probability of suffering 
from internal disease.
It is noticeable that one of our drug-induced cases 
showed deposition of both IgA and IgG at the BMZ. 
This is in contrast to an American study describing 
no deposition of IgG, although they found a weak 
deposition of C3 in 3 of 6 patients (10). None of our 
drug-induced cases exhibited C3 deposition. One child 
presented mixed IgA/IgG deposits while C3 was found 
only in the adult idiopathic group where it was present in 
4 out of 10 patients. One patient (No. 23) had granular 
deposits of IgA along with the linear deposition, which 
made it impossible for the pathologist to differentiate 
between LAD and dermatitis herpetiformis. Hence, the 
diagnosis in the latter case was established based on the 
clinical characteristics, the lack of symptoms from the 
intestines, and a negative screening for coeliac disease. 
Mixed deposits are previously described in a number of 
cases (11–18). Their significance remains uncertain but 
it may be confusing and make the differential diagnosis 
more difficult.
It is always difficult to say whether a certain eruption 
is in fact caused by a certain drug although different al-
gorithms exist to clarify this judgement, e.g. the Naranjo 
algorithm (19). We have applied the Naranjo algorithm 
for our suspected drug-induced cases, and the results 
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are listed in Table II. Only one of the 6 cases (No. 11) 
reaches the probability score of 5 meaning probable 
adverse drug reaction (ADR) due to one previous case 
report of penicillin as an inducer of LAD (20). The other 
5 cases are assigned the probability score possible ADR.
In our opinion, a close time-relationship between drug 
introduction followed by the development of a rash, 
and disappearance of the rash upon drug withdrawal, 
support the suspicion that the rash is in fact induced 
by the drug. In our case-series 5 of 6 patients with 
suspected drug-induced LAD remitted within a few 
months (1–5) upon drug withdrawal. Amongst the 
idiopathic cases the mean duration of treatment was 
significantly longer: 6.9 years.
One of the suspected drug-induced cases was remitted 
only after 2 years, but in this case there was an asso-
ciation with bladder cancer as well, which previously 
has been described in association with LAD (21). As 
a consequence of the results above, we have chosen to 
differentiate between an idiopathic and a drug-induced 
group as described elsewhere in the literature (22). 
Recently, however, a review found no strong evidence 
that LAD is in fact induced by certain drugs, and the 
entity was questioned (23). 
LAD has been described in association with malig-
nancy as well as related to autoinflammatory conditions 
(for instance inflammatory bowel disease and Sjögren’s 
disease) (24–27). One of the patients with suspected 
drug-induced LAD was diagnosed with cancer of the 
bladder and one of the patients with idiopathic (non 
drug-induced) LAD was diagnosed with coeliac disease, 
myelodysplastic syndrome and paroxysmal nocturnal 
haemoglobinuria, associations that might be relevant. 
The last mentioned patient had active skin disease until 
her death 5 years later. The patient with the longest 
disease duration (22 years), however, was otherwise 
completely healthy.
We found a slight male predominance (but not statisti-
cally significant) in our study in agreement with studies 
from Tunisia (28), Iran (29), North India (30) and Kuwait 
(9). Other studies from Poland and Tunisia, however, 
showed a slight female predominance (31, 32). 
The mean age at disease onset for the children in our 
group was 2.7 years (range 11 months–4 years). This 
is a little lower than the ages reported in Tunisia: 5.5 
years (33) and 7.5 years (28), North India: 3.5 years 
(30) and Kuwait: 6.8 years (9).
It is difficult to give a precise estimate of disease 
duration. Our patients were treated until remission and 
then, at some point, we started tapering the treatment. 
Sometimes a minor relapse occurred and dosing of treat-
ment was increased. The mean treatment time for LAD 
in children at our department was 3.2 years (range 2–6 
years, median 3 years). It is interesting, that the mean 
duration of disease in Tunisia is only 14 months (33) 
and in North India 8 months (30). A possible explana-
tion for this phenomenon could be a shorter follow-up 
period in these studies.
In our department dapsone has been the drug of 
choice for LAD in adults, sometimes together with 
prednisone, to induce remission. In the childhood group 
half of the patients were initially treated with dapsone 
and half with sulphapyridine. None of these treatments 
seemed better than the other in our hands since 6 of 7 
children underwent treatment with both drugs due to 
side effects or poor response and some patients were 
even treated with prednisone before remission occur-
red. In the literature, dapsone seems to be the drug of 
choice in both children and adults (9, 28, 30, 33–35).
Conclusion
LAD elicits a biphasic course affecting primarily young 
children and adults after their 5th decade. The disease 
is often mistaken for other bullous diseases such as 
impetigo (children) or bullous pemphigoid (adults). It 
is important to make the correct diagnosis, based on the 
clinical and immune histological findings, in order to 
provide the optimum treatment and care for the patient.
In general, dapsone must be regarded as the drug of 
choice for LAD. For childhood LAD, however, sul-
phapyridine seems to be just as effective and might be 
easier to administer. In some cases additional systemic 
corticosteroids are needed.
With an estimated incidence rate of 0.67/million/year 
in our region, LAD is a rare but benign condition that 
in most cases can be effectively treated.
The authors declare no conflict of interest.
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